The expert in hematology/oncology discussed what research he is most looking forward to seeing the results of at the meeting.
Satya Das, MD, MSCI
Advertisement
Articles by Satya Das, MD, MSCI
The expert in hematology/oncology discussed the implications of a study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
The expert in hematology/oncology discussed the results of a study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
The expert in hematology/oncology spoke about the study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Response Rates Show Promise in Phase 1 Trial Involving ASCT in Metastatic PDAC
2
Case 2: Patient With High-Risk RRMM Relapsing After BCMA CAR T-Cell Therapy
3
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
4
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
5
